HypertensionCHPCNCT06081010
FCHV-HTN Implementation Trial in Nepal
A study testing Community Health Worker Intervention in people with Hypertension, run by Yale University at 1 site in Nepal.
Trial summary
The goal of this hybrid type III study incorporating a cluster-randomized trial is to assess the effect of a community health worker-led hypertension prevention and control program (CHPC) on the implementation outcomes and clinical outcomes among patient with hypertension in central Nepal. Read more about this study
- Who is it for?
- Ages 30 years and older
- Conditions the study is for
- Hypertension
- What is being tested?
- Community Health Worker Intervention
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 3,572 participants
- Where
- 1 siteNepal
- Study dates
- 2 Dec 2024to 31 Dec 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 30 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- -High blood pressure (BP) of 140/90 mmHg or higher.
Who cannot join
- Severe illness requiring bed rest
- Pregnant women, due to their special health needs
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Community Health Worker Led Hypertension Prevention and Control (CHPC) in Nepal: An Implementation Trial
The goal of this hybrid type III study incorporating a cluster-randomized trial is to assess the effect of a community health worker-led hypertension prevention and control program (CHPC) on the implementation outcomes and clinical outcomes among patient with hypertension in central Nepal. The main questions it aims to answer are:
- What is the level of implementation outcomes, including reach, adoption, implementation fidelity, and maintenance of the CHPC implementation strategy at the patient, provider, and health system levels?
Read more
2: What is the effectiveness of the CHPC implementation strategy compared to facility-based intervention on systolic BP via a cluster randomized controlled trial.
3: What is the implementation cost and cost-effectiveness of the CHPC implementation strategy?
Participants will receive four follow-up group meetings or home visits every three months for a year by a community health worker. Researchers will compare if there is a significant difference in systolic blood pressure between those who receive this intervention and those who do not receive the intervention in the same community.
Read the detailed description
INTRODUCTION:
Hypertension (HTN) is a global public health challenge. About 13.5% of global total mortality is attributed to high blood pressure (BP) worldwide. In addition, about 54% of strokes and 47% of coronary heart disease worldwide were attributable to high BP. In Nepal, the adult HTN prevalence is 25%, similar to the global prevalence. Community Health Workers (CHWs) are the frontline pillars of community-based health programs in Nepal. Through CHW, this investigation aims to influence HTN control and behavior change among adults and society at large. By providing a replicable model for increasing HTN awareness, treatment, and control in Nepal, investigators will accelerate the integration of effective intervention into practice, providing an example of amelioration of the well-documented delays in moving tested interventions to practice. To ensure relevance to policymakers, the investigators will follow the principles of 'practical trials that include: (a) implementing the strategy, (b) facilitating and evaluating the maintenance of the strategy beyond the implementation phase; (c) using multiple evaluation measures relevant to decision makers, including reach, adoption, and cost; and (d) evaluating effectiveness across multiple outcomes, with a plan to triangulate findings from across multiple data sources using both qualitative and quantitative measures.
METHODS:
Investigators will conduct a Hybrid type III effectiveness-implementation design focusing primarily on implementation outcomes while also collecting effectiveness outcomes as they relate to the uptake or fidelity of the intervention. The primary implementation outcomes (aim 1) - reach, adoption, implementation and maintenance - are selected to answer the central research question of this study and will be assessed using a non-inferiority design. Investigators will assess these outcomes in the intervention group using data from the process evaluation in intervention health facilities. For each outcome, the null hypothesis is that the percentages are equivalent to a set target or greater. Thus, if the program is successful, investigators will be able to say with 95% confidence that these high standards have been met. To measure the effectiveness (aim 2), investigators will use a cluster-randomized design to assess change in mean systolic BP in the intervention group compared to the control group at 12 months after the intervention. Investigators will also measure cost and estimate incremental cost per participant with awareness on and control of high BP (aim 3).
STUDY SETTING:
We will conduct the study in Sindhupalchowk district, one of the largest districts in Bagmati province, Nepal, consisting of nine rural and three urban municipalities. Basic health facilities in the Sindhupalchowk district province that host CHWs will be included. In the study districts, there are 102 basic health facilities, and approximately 687 CHWs. These CHWs are female community health volunteers (FCHV) who provide basic health services in Nepal, historically focused on maternal and child health.
INTERVENTION: FCHV-led Hypertension Prevention and Control (CHPC) Program
Fundamentally, the intervention involves task-shifting of HTN management roles to primary care and community-level health workers, integrating the five components of the evidence-based interventions outlined in the Package of Essential Non-Communicable Diseases (PEN) protocol 1 and 2:
- BP measurement and monitoring;
- identify high BP individuals and report to health facility;
- provide one-on-one counseling and lifestyle modification goal setting including sodium reduction, healthy diet, alcohol abstinence, physical activity, and medication;
- BP monitoring of HTN patients; and
- medication adherence of HTN patients, delivered by the FCHVs trained for the intervention.
The intervention will be conducted over a fiscal year, and repeated during the maintenance.
IMPLEMENTATION STRATEGIES:
To address barriers of implementing the intervention, we will incorporate the following strategies and core components:
- Leadership support and ongoing program promotion - Health Coordinators from Provincial MoH will participate in the planning, execution and monitoring of the study. In provincial MoH health review meetings, hypertension-related indicators (proportion of population screened, HTN detected, HTN under medication, HTN control) will be discussed using the government's health management information system data.
- Capacity building - Healthcare workers training; FCHV training; Coaching and technical support from healthcare workers to FCHV in a monthly meeting
- CHW home visit and group meeting - 1st visit: introduction, rapport building, goal setting, BP monitoring; 2nd- 4th visit: BP monitoring, action and reflection, discussing problems faced in achieving their goals and implementing their action plans
- Social network - Monthly meeting of health care workers in the municipality; Monthly meeting of FCHVs in the health facility
DATA SOURCES:
Quantitative - Participant Survey; Anthropometric Measurement; Blood Pressure Measurement; Healthcare Provider Survey; Process Tracking
Qualitative - Periodic Reflection; Meeting Observations; Focus Group Discussions; Key Informant Interviews
The primary aim is to determine the extent to which this implementation model meets acceptable rates of program adoption, implementation, reach and maintenance of the CHPC program. For assessing the adoption, implementation, reach, and maintenance, we will include all intervention health facilities. To assess the effectiveness, we are planning for patients to be enrolled over six months.
- Conditions
- Hypertension
- Being tested
- Community Health Worker Intervention
- Keywords
- Hypertension, Community Health Worker, Implementation Trial
- Medical subject headings
- Hypertension
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Community Health Worker InterventionBehavioural
Trained CHWs will hold group meetings or home visits using a locally adapted manual for HTN management. CHWs will visit homes in their areas and measure BP. High BP clients will be taken to the nearest health center. CHWs will enroll individuals with preHTN and HTN and conduct 4 follow-up group meetings or home visits with them every 3 months. Participants will be invited to attend CHW lead group-based counseling. For those with uncontrolled HTN who have difficulty adhering to prescribed HTN management and not willing or able to attend group meetings, CHWs will conduct follow-up home visits. First meeting (about 90 minutes), CHWs will explain purpose of the meeting and discuss HTN and its consequences. CHWs will apply techniques to initiate dialogue and reflection regarding lifestyle modifications and choose goals based on PEN protocol-2, BP monitoring, and antihypertensive medication use. In subsequent meetings (about 60 minutes), the CHWs will measure BP and address ongoing problems.
| Study group | Role | What they receive |
|---|---|---|
| Intervention arm | Experimental | Community Health Worker Intervention Receives: Behavioral: Community Health Worker Intervention |
| Control Group | No intervention | Usual care that includes patients visit to health facility based on felt need |
What is being measured
The primary outcome is the main question the study is designed to answer.
Reach
Percentage of CHWs implementing the program
Measured: 12 months
Adoption
Percentage of the health facilities asked to participate in adopting the program
Measured: 12 months
Program implementation
Percent of the health facility will implement a minimum standard to program implementation
Measured: 12 months
Maintenance
Percentage of the health facility that will implement a minimum standard to program implementation during the maintenance period
Measured: 24 months
Secondary outcomes (12)
Blood Pressure
Difference in mean systolic and diastolic blood pressure (mmHg) between study arms
Measured: 12 months
Hypertension Diagnosis Awareness
Difference in proportion of patients aware of their HTN diagnosis between study arms
Measured: 12 months
Blood Pressure Control
Difference in proportion of patients with controlled BP (less than 140/90 mmHg) between study arms
Measured: 12 months
Physical activity
Proportion of patients with low physical activity (less than 600 MET-minutes per week) between study arms
Measured: 12 months
Fruits and Vegetables
Proportion of participants with intake of 5 or more servings of fruits and vegetables per day between study arms
Measured: 12 months
Medication
Proportion of participants adherent to hypertension medication between study arms
Measured: 12 months
Affordability
Total incremental costs of care in the study arms
Measured: 12 months
Equity
Household economic impacts in the study arms by measurement of financial and economic costs. Disaggregated analysis, based on gender, ethnicity, and socio-economic status, will be conducted to assess disparities among the study groups
Measured: 12 months
Scalability
Scenario based and sensitivity analysis for scaling up this intervention at the national level
Measured: 12 months
Cost-effectiveness
calculation of incremental cost effectiveness ratios (ICERs) per person per QALY gained
Measured: 12 months
Cost-effectiveness
calculation of incremental cost effectiveness ratios (ICERs) per person per BP control gained
Measured: 12 months
Scalability
Scenario based and sensitivity analysis for scaling up this intervention at the provinical level
Measured: 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Oct 2023
- Study start2 Dec 2024
- Primary completion31 Dec 2027 (estimated)
- Study completion31 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for HypertensionStudies of the same condition, open and under way.
- More trials run by Yale UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 3,572 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Yale University
- Sponsor type
- University, hospital or other
- Collaborators
- Dhulikhel Hospital, Institute for Implementation Science and Health, National Heart, Lung, and Blood Institute (NHLBI)
- Responsible party
- Sponsor
- Investigators
- Donna Spiegelman, ScD, Principal investigator, Yale University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06081010
- Sponsor's protocol ID
- 2000036053
- Other IDs
- 1R01HL169421-01
- Acronym
- CHPC
- Status last verified
- Sep 2026
- First submitted
- 6 Oct 2023
- Last updated
- 24 Sep 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Shrestha A, Sapkota S, Timalsena D, Sharma P, Porter AK, Cameron DB, Hagaman A, Neupane D, Dhimal M, Mali S, Poudel L, Sagtani RA, Paneru B, Paudel P, Joshi A, Chaulagain DR, Karmacharya RM, Spiegelman D. Community-based HyPertension Control (CHPC) in Nepal: Cluster randomized implementation trial protocol. Public Health Pract (Oxf). 2026 Mar 20;11:100772. doi: 10.1016/j.puhip.2026.100772. eCollection 2026 Jun.
PubMed 41952878
Study at a glance
From the registry record, last updated by the sponsor on 24 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Community Health Worker Led Hypertension Prevention and Control (CHPC) in Nepal: An Implementation Trial
- ClinicalTrials.gov ID
- NCT06081010
- Acronym / sponsor ID
- CHPC / 2000036053
- Conditions
- Hypertension
- Keywords
- Hypertension, Community Health Worker, Implementation Trial
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 3,572 participants (estimated)
- Lead sponsor
- Yale UniversityUniversity, hospital or other
- Collaborators
- Dhulikhel Hospital, Institute for Implementation Science and Health, National Heart, Lung, and Blood Institute (NHLBI)
- Study start
- 2 Dec 2024 (actual)
- Primary completion
- 31 Dec 2027 (estimated)
- Study completion
- 31 Dec 2027 (estimated)
- First posted
- 12 Oct 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this hybrid type III study incorporating a cluster-randomized trial is to assess the effect of a community health worker-led hypertension prevention and control program (CHPC) on the implementation outcomes and clinical outcomes among patient with hypertension in central Nepal. The main questions it aims to answer are:
- What is the level of implementation outcomes, including reach, adoption, implementation fidelity, and maintenance of the CHPC implementation strategy at the patient, provider, and health system levels?
2: What is the effectiveness of the CHPC implementation strategy compared to facility-based intervention on systolic BP via a cluster randomized controlled trial.
3: What is the implementation cost and cost-effectiveness of the CHPC implementation strategy?
Participants will receive four follow-up group meetings or home visits every three months for a year by a community health worker. Researchers will compare if there is a significant difference in systolic blood pressure between those who receive this intervention and those who do not receive the intervention in the same community.
Detailed description
INTRODUCTION:
Hypertension (HTN) is a global public health challenge. About 13.5% of global total mortality is attributed to high blood pressure (BP) worldwide. In addition, about 54% of strokes and 47% of coronary heart disease worldwide were attributable to high BP. In Nepal, the adult HTN prevalence is 25%, similar to the global prevalence. Community Health Workers (CHWs) are the frontline pillars of community-based health programs in Nepal. Through CHW, this investigation aims to influence HTN control and behavior change among adults and society at large. By providing a replicable model for increasing HTN awareness, treatment, and control in Nepal, investigators will accelerate the integration of effective intervention into practice, providing an example of amelioration of the well-documented delays in moving tested interventions to practice. To ensure relevance to policymakers, the investigators will follow the principles of 'practical trials that include: (a) implementing the strategy, (b) facilitating and evaluating the maintenance of the strategy beyond the implementation phase; (c) using multiple evaluation measures relevant to decision makers, including reach, adoption, and cost; and (d) evaluating effectiveness across multiple outcomes, with a plan to triangulate findings from across multiple data sources using both qualitative and quantitative measures.
METHODS:
Investigators will conduct a Hybrid type III effectiveness-implementation design focusing primarily on implementation outcomes while also collecting effectiveness outcomes as they relate to the uptake or fidelity of the intervention. The primary implementation outcomes (aim 1) - reach, adoption, implementation and maintenance - are selected to answer the central research question of this study and will be assessed using a non-inferiority design. Investigators will assess these outcomes in the intervention group using data from the process evaluation in intervention health facilities. For each outcome, the null hypothesis is that the percentages are equivalent to a set target or greater. Thus, if the program is successful, investigators will be able to say with 95% confidence that these high standards have been met. To measure the effectiveness (aim 2), investigators will use a cluster-randomized design to assess change in mean systolic BP in the intervention group compared to the control group at 12 months after the intervention. Investigators will also measure cost and estimate incremental cost per participant with awareness on and control of high BP (aim 3).
STUDY SETTING:
We will conduct the study in Sindhupalchowk district, one of the largest districts in Bagmati province, Nepal, consisting of nine rural and three urban municipalities. Basic health facilities in the Sindhupalchowk district province that host CHWs will be included. In the study districts, there are 102 basic health facilities, and approximately 687 CHWs. These CHWs are female community health volunteers (FCHV) who provide basic health services in Nepal, historically focused on maternal and child health.
INTERVENTION: FCHV-led Hypertension Prevention and Control (CHPC) Program
Fundamentally, the intervention involves task-shifting of HTN management roles to primary care and community-level health workers, integrating the five components of the evidence-based interventions outlined in the Package of Essential Non-Communicable Diseases (PEN) protocol 1 and 2:
- BP measurement and monitoring;
- identify high BP individuals and report to health facility;
- provide one-on-one counseling and lifestyle modification goal setting including sodium reduction, healthy diet, alcohol abstinence, physical activity, and medication;
- BP monitoring of HTN patients; and
- medication adherence of HTN patients, delivered by the FCHVs trained for the intervention.
The intervention will be conducted over a fiscal year, and repeated during the maintenance.
IMPLEMENTATION STRATEGIES:
To address barriers of implementing the intervention, we will incorporate the following strategies and core components:
- Leadership support and ongoing program promotion - Health Coordinators from Provincial MoH will participate in the planning, execution and monitoring of the study. In provincial MoH health review meetings, hypertension-related indicators (proportion of population screened, HTN detected, HTN under medication, HTN control) will be discussed using the government's health management information system data.
- Capacity building - Healthcare workers training; FCHV training; Coaching and technical support from healthcare workers to FCHV in a monthly meeting
- CHW home visit and group meeting - 1st visit: introduction, rapport building, goal setting, BP monitoring; 2nd- 4th visit: BP monitoring, action and reflection, discussing problems faced in achieving their goals and implementing their action plans
- Social network - Monthly meeting of health care workers in the municipality; Monthly meeting of FCHVs in the health facility
DATA SOURCES:
Quantitative - Participant Survey; Anthropometric Measurement; Blood Pressure Measurement; Healthcare Provider Survey; Process Tracking
Qualitative - Periodic Reflection; Meeting Observations; Focus Group Discussions; Key Informant Interviews
The primary aim is to determine the extent to which this implementation model meets acceptable rates of program adoption, implementation, reach and maintenance of the CHPC program. For assessing the adoption, implementation, reach, and maintenance, we will include all intervention health facilities. To assess the effectiveness, we are planning for patients to be enrolled over six months.
Study design
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Intervention arm | Experimental | Behavioral: Community Health Worker InterventionCommunity Health Worker Intervention |
| Control Group | No intervention | –Usual care that includes patients visit to health facility based on felt need |
Who may qualify
- Ages
- 30 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- -High blood pressure (BP) of 140/90 mmHg or higher.
Key exclusion criteria (2 listed)
- Severe illness requiring bed rest
- Pregnant women, due to their special health needs
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Community Health Worker InterventionTrained CHWs will hold group meetings or home visits using a locally adapted manual for HTN management. CHWs will visit homes in their areas and measure BP. High BP clients will be taken to the nearest health center. CHWs will enroll individuals with preHTN and HTN and conduct 4 follow-up group meetings or home visits with them every 3 months. Participants will be invited to attend CHW lead group-based counseling. For those with uncontrolled HTN who have difficulty adhering to prescribed HTN management and not willing or able to attend group meetings, CHWs will conduct follow-up home visits. First meeting (about 90 minutes), CHWs will explain purpose of the meeting and discuss HTN and its consequences. CHWs will apply techniques to initiate dialogue and reflection regarding lifestyle modifications and choose goals based on PEN protocol-2, BP monitoring, and antihypertensive medication use. In subsequent meetings (about 60 minutes), the CHWs will measure BP and address ongoing problems. | Behavioural | Intervention arm |
Primary outcome
Reach
Time frame: 12 months
Percentage of CHWs implementing the program
Adoption
Time frame: 12 months
Percentage of the health facilities asked to participate in adopting the program
Program implementation
Time frame: 12 months
Percent of the health facility will implement a minimum standard to program implementation
Maintenance
Time frame: 24 months
Percentage of the health facility that will implement a minimum standard to program implementation during the maintenance period
12 secondary outcomes
Blood Pressure
Time frame: 12 months
Hypertension Diagnosis Awareness
Time frame: 12 months
Blood Pressure Control
Time frame: 12 months
Physical activity
Time frame: 12 months
Fruits and Vegetables
Time frame: 12 months
Medication
Time frame: 12 months
Affordability
Time frame: 12 months
Equity
Time frame: 12 months
Scalability
Time frame: 12 months
Cost-effectiveness
Time frame: 12 months
Cost-effectiveness
Time frame: 12 months
Scalability
Time frame: 12 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Sep 2026.
- Derived from this study: PubMed 41952878Shrestha A, Sapkota S, Timalsena D, Sharma P, Porter AK, Cameron DB, Hagaman A, Neupane D, Dhimal M, Mali S, Poudel L, Sagtani RA, Paneru B, Paudel P, Joshi A, Chaulagain DR, Karmacharya RM, Spiegelman D. Community-based HyPertension Control (CHPC) in Nepal: Cluster randomized implementation trial protocol. Public Health Pract (Oxf). 2026 Mar 20;11:100772. doi: 10.1016/j.puhip.2026.100772. eCollection 2026 Jun.
- Individual participant dataSharing planned: No
Related trials for Hypertension
RecruitingPhase 2
Spironolactone for Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension
Active, not recruitingPhase 1
Study of Intravenous ZMA001 in Healthy Subjects
Pulmonary Arterial Hypertension PAH
Active, not recruitingObservational study
An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH
Pulmonary Hypertension, Interstitial Lung Disease
RecruitingObservational study
Clevidipine for the Antihypertensive Treatment of Acute Intracerebral Hemorrhage
Intracerebral Hemorrhage, Stroke
RecruitingPhase 1/2
HS235 Study in Overweight and Obese Participants With Combined Pre and Post-Capillary Pulmonary Hypertension Due to Heart Failure With Preserved Ejection Fraction
Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Donna Spiegelman, ScD principal investigator
Yale University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Community Health Worker Intervention in people with Hypertension, run by Yale University at 1 site in Nepal.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 24 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Nepal. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Reach (time frame: 12 months). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06081010, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Sep 2026; AzTrials last refreshed its copy on 31 Oct 2026.